Advertisement News Archives - Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 19, 2019

Xynomic Research Institute successfully designs series of potent RET kinase inhibitors

Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.

Xynomic Research Institute successfully designs series of potent RET kinase inhibitors